Comparison of Intratympanic and Systemic Steroid Therapy as Primary Treatments for Idiopathic Sudden Sensorial Hearing Loss

Sayaka Fuji; Ayako Takeuchi; Akifumi Kariya; Naoki Akisada; Takahisa Koyama; Iku Fujisawa; Koji Hamada; Hisashi Ishihara; Seiko Akagi

doi:10.1055/s-0043-1770369

International Journal of Practical Otolaryngology, Inhaltsverzeichnis

CC BY-NC-ND 4.0 · International Journal of Practical Otolaryngology 2023; 06(01): e24-e30
DOI: 10.1055/s-0043-1770369

Original Article

Comparison of Intratympanic and Systemic Steroid Therapy as Primary Treatments for Idiopathic Sudden Sensorial Hearing Loss

Sayaka Fuji

¹Department of Otolaryngology, Japanese Red Cross Okayama Hospital, Okayama, Japan

,

Ayako Takeuchi

¹Department of Otolaryngology, Japanese Red Cross Okayama Hospital, Okayama, Japan

,

Akifumi Kariya

²Department of Otolaryngology, Japanese Red Cross Society, Himeji Hospital, Himeji, Hyogo, Japan

,

Naoki Akisada

³Department of Otolaryngology—Head and Neck Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan

,

Takahisa Koyama

¹Department of Otolaryngology, Japanese Red Cross Okayama Hospital, Okayama, Japan

,

Iku Fujisawa

³Department of Otolaryngology—Head and Neck Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan

,

Koji Hamada

¹Department of Otolaryngology, Japanese Red Cross Okayama Hospital, Okayama, Japan

,

Hisashi Ishihara

¹Department of Otolaryngology, Japanese Red Cross Okayama Hospital, Okayama, Japan

⁴Kobayashi Ear, Nose & Throat Clinic, Kurashiki, Okayama, Japan

,

Seiko Akagi

¹Department of Otolaryngology, Japanese Red Cross Okayama Hospital, Okayama, Japan

› Institutsangaben

Abstract

Recently, intratympanic steroid (ITS) therapy has been used as a primary or salvage treatment for idiopathic sudden sensorineural hearing loss (ISSHL). In the present study, we retrospectively compared the efficacies of ITS and systemic steroid (SS) therapies as primary treatments for ISSHL. This study included 112 patients treated for ISSHL at our hospital, of which 44 received ITS therapy and 68 received SS therapy. Regarding patient background characteristics, the mean age (76 vs. 65 years, p < 0.0001) and percentage of patients with diabetes mellitus (55 vs. 18%, p < 0.0001) were significantly higher in the ITS group than in the SS group, whereas the rate of prior steroid use was lower in the ITS group than in the SS group (9 vs. 31%, p = 0.0068). After 3 weeks, the treatment response was cure, marked recovery, recovery, and no change in 11, 9, 8, and 16 patients in the ITS group and 32, 11, 5, and 20 patients in the SS group, respectively. Accordingly, the SS group was found to have a significantly higher cure rate than the ITS group (47 vs. 25%, p = 0.0191), with similar findings after propensity score matching (48 vs. 22%, p = 0.0461). Therefore, SS therapy is recommended as a primary treatment for ISSHL in patients who are not old or at a high risk of SS therapy-associated complications.

Keywords

idiopathic sudden sensorineural hearing loss - intratympanic steroid therapy - primary treatment

Volltext

Referenzen

References
1 Wilson WR, Byl FM, Laird N. The efficacy of steroids in the treatment of idiopathic sudden hearing loss. A double-blind clinical study. Arch Otolaryngol 1980; 106 (12) 772-776
2 Japan Audiological Society. Clinical Practice Guidelines for the Diagnosis and Management of Acute Sensorineural Hearing Loss. Tokyo: Kanehara Shuppan; 2018: 58-59
3 Rauch SD, Halpin CF, Antonelli PJ. et al. Oral vs intratympanic corticosteroid therapy for idiopathic sudden sensorineural hearing loss: a randomized trial. JAMA 2011; 305 (20) 2071-2079
4 Battaglia A, Burchette R, Cueva R. Combination therapy (intratympanic dexamethasone + high-dose prednisone taper) for the treatment of idiopathic sudden sensorineural hearing loss. Otol Neurotol 2008; 29 (04) 453-460
5 Hong SM, Park CH, Lee JH. Hearing outcomes of daily intratympanic dexamethasone alone as a primary treatment modality for ISSHL. Otolaryngol Head Neck Surg 2009; 141 (05) 579-583
6 Dispenza F, Amodio E, De Stefano A. et al. Treatment of sudden sensorineural hearing loss with transtympanic injection of steroids as single therapy: a randomized clinical study. Eur Arch Otorhinolaryngol 2011; 268 (09) 1273-1278
7 Lim HJ, Kim YT, Choi SJ. et al. Efficacy of 3 different steroid treatments for sudden sensorineural hearing loss: a prospective, randomized trial. Otolaryngol Head Neck Surg 2013; 148 (01) 121-127
8 Swachia K, Sharma D, Singh J. Efficacy of oral vs. intratympanic corticosteroids in sudden sensorineural hearing loss. J Basic Clin Physiol Pharmacol 2016; 27 (04) 371-377
9 Tsounis M, Psillas G, Tsalighopoulos M, Vital V, Maroudias N, Markou K. Systemic, intratympanic and combined administration of steroids for sudden hearing loss. A prospective randomized multicenter trial. Eur Arch Otorhinolaryngol 2018; 275 (01) 103-110
10 Ermutlu G, Süslü N, Yılmaz T, Saraç S. Sudden hearing loss: an effectivity comparison of intratympanic and systemic steroid treatments. Eur Arch Otorhinolaryngol 2017; 274 (10) 3585-3591
11 Chandrasekhar SS, Tsai Do BS, Schwartz SR. et al. Clinical practice guideline: sudden hearing loss (update). Otolaryngol Head Neck Surg 2019; 161 (1 Suppl): S1-S45
12 Kitoh R, Nishio SY, Ogawa K. et al. Nationwide epidemiological survey of idiopathic sudden sensorineural hearing loss in Japan. Acta Otolaryngol 2017; 137 (Suppl. 565) S8-S16
13 Bae SC, Noh HI, Jun BC. et al. Efficacy of intratympanic steroid therapy for idiopathic sudden sensorineural hearing loss: comparison with systemic steroid therapy and combined therapy. Acta Otolaryngol 2013; 133 (05) 428-433
14 Kakehata S, Sasaki A, Futai K, Kitani R, Shinkawa H. Daily short-term intratympanic dexamethasone treatment alone as an initial or salvage treatment for idiopathic sudden sensorineural hearing loss. Audiol Neurotol 2011; 16 (03) 191-197
15 Kito R, Mori K, Usami S. The evaluation of the intratympanic steroid therapy for idiopathic sudden sensorineural hearing loss. Pract Otorhinolaryngol (Basel) 2015; 108: 267-272
16 Kara E, Çetik F, Tarkan O, Sürmelioğlu O. Modified intratympanic treatment for idiopathic sudden sensorineural hearing loss. Eur Arch Otorhinolaryngol 2010; 267 (05) 701-707
17 Tsai YJ, Liang JG, Wu WB, Ding YF, Chiang RP, Wu SM. Intratympanic injection with dexamethasone for sudden sensorineural hearing loss. J Laryngol Otol 2011; 125 (02) 133-137
18 Han CS, Park JR, Boo SH. et al. Clinical efficacy of initial intratympanic steroid treatment on sudden sensorineural hearing loss with diabetes. Otolaryngol Head Neck Surg 2009; 141 (05) 572-578
19 Robey AB, Morrow T, Moore GF. Systemic side effects of transtympanic steroids. Laryngoscope 2010; 120 (Suppl. 04) S217
20 Labatut T, Daza MJ, Alonso A. Intratympanic steroids as primary initial treatment of idiopathic sudden sensorineural hearing loss. The Hospital Universitario Ramón y Cajal experience and review of the literature. Eur Arch Otorhinolaryngol 2013; 270 (11) 2823-2832
21 Fujita N, Yamanaka T, Kitahara T. Treatment of tympanic membrane perforation with intratympanic steroid injection therapy. J Jpn Soc Head Neck Surg 2015; 25: 457-461
22 Kim YH, Lee DY, Lee DH, Oh S. Tympanic membrane perforation after intratympanic steroid injection: a systematic review and meta-analysis. Otolaryngol Head Neck Surg 2022; 166 (02) 249-259
23 Hiraga Y, Wasano K, Kawasaki T. et al. Combined intratympanic and systemic steroid therapy for idiopathic sensorineural hearing loss. J Otolaryngol Jpn 2021; 124: 35-42